Novel BMP2K::PDGFRA fusion in an unusual myeloid/lymphoid neoplasm with eosinophilia
Given that PDGFRA fusions with novel fusion partners may respond to tyrosine kinase inhibitor therapy, partner agnostic testing methods should be considered either up front or as reflex testing in patients with myeloid and/or lymphoid neoplasms with blood, bone marrow, or tissue eosinophilia.
Authors
- Sophia Yohe (ORCID: https://orcid.org/0000-0003-2235-9930)
- Mehrnoosh Tashakori (ORCID: https://orcid.org/0000-0002-0973-3011)
- Ravi Tej Bommu
- Laila O. Mnayor
Institutions
- Hartford Hospital (US)
- University of Minnesota (US)
- University of Iowa Health Care (US)
Publication Details
- Journal
- Journal of Hematopathology
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1007/s12308-025-00661-7
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 0.00